Team

Kazumi is the CEO of Redona Therapeutics, which she co-founded alongside prominent Harvard investigators. She is passionate about creating companies focused on novel and emerging areas of biology. Previously, Kazumi was co-founder and CEO of Mitobridge, a start-up pioneering mitochondrial drugs for muscle and kidney diseases. Mitobridge was acquired by Astellas in 2018.

She was also a co-founder and start-up CEO of Epizyme, a leader in novel epigenetic therapeutics, and Primera Diagnostics, a molecular diagnostics company focused on infectious disease and oncology. She has also been a Managing Director at MPM Capital. Kazumi started her career at Abbott and rose through the ranks at Millennium to become SVP of Drug Discovery. She is presently a board member of the Sanford Burnham Institute. Kazumi received her Ph.D. in Synthetic Chemistry from UC Berkeley.

Kleem has extensive leadership experience within the biotech and pharmaceutical industry with a focus on business development, strategy, finance, and general operations. Most recently, he was CBO of Checkmate Pharmaceuticals, where he was instrumental in the company’s Series C financing, IPO, and subsequent sale to Regeneron.  Kleem has held roles of increasing responsibility across multiple organizations including as Head of Business Development & Licensing at Biogen and previously as a transaction leader in Business Development at Takeda. He began his business development career at Novartis, where he was a team leader and led deals across multiple therapeutic areas. Prior to Novartis, he was the head of a medicinal chemistry lab at Gilead Sciences. Dr. Chaudhary holds a PhD in chemistry from the University of North Carolina at Chapel Hill and a BSc in chemistry from the University of Winnipeg.

Darren is Vice President of Medicinal Chemistry at Redona, bringing over 20 years of Drug Discovery experience to the team.  Darren has held positions of increasing responsibility at both biotech and big pharma, starting his career at Array Biopharma before transitioning to Sanofi and then Epizyme prior to joining 28-7.  Darren is passionate about finding novel solutions to impact patients’ lives and working in a fast-paced multidisciplinary organization.  Darren did his undergraduate and Ph.D. research in the UK before a 2-year Post Doc at Pitt.  Darren is a co-author / co-inventor on >30 peer reviewed articles and patent applications with 20 published patents.